文献速递重症综合管理与镇静镇痛

探索氯胺酮镇痛镇静的使用及其对危重成人新发谵妄的影响

Exploring Ketamine Analgosedation Use and Its Effect on Incident Delirium in Critically Ill Adults.
PubMed 文献 · Crit Care Explor · 2021-09-28
一句话结论单中心回顾性队列二次分析提示,氯胺酮镇痛镇静与ICU谵妄风险独立相关(aOR 5.60),但谵妄特征与结局无差异。

该研究为荷兰单中心36张床混合ICU的回顾性队列二次亚组分析,纳入2016年7月至2020年2月连续成人患者,排除择期术后、预期生存<48小时、入ICU时已谵妄或氯胺酮使用前已谵妄者。925例中332例(36%)发生谵妄,谵妄组氯胺酮使用比例更高(16% vs 0.7%,p<0.01)。多因素logistic回归显示氯胺酮使用(aOR 5.60,95%CI 1.09-29.15)、年龄、昏迷、阿片类及苯二氮䓬类使用均与谵妄独立相关。氯胺酮与非氯胺酮谵妄患者的谵妄持续时间、运动亚型、治疗及结局无差异。作者认为氯胺酮镇痛镇静可能增加ICU谵妄,需前瞻性研究验证。

要点

  • 单中心925例成人ICU队列中36%发生谵妄,谵妄组氯胺酮暴露率16% vs 非谵妄组0.7%(p<0.01)。
  • 校正年龄、Charlson评分、SOFA评分、昏迷、苯二氮䓬类及阿片类后,氯胺酮使用与谵妄独立相关(aOR 5.60,95%CI 1.09-29.15)。
  • 阿片类(aOR 171.17,95%CI 66.45-553.68)和苯二氮䓬类(aOR 34.07,95%CI 8.12-235.34)与谵妄的关联强度远高于氯胺酮。
  • 氯胺酮与非氯胺酮谵妄患者的谵妄持续时间、运动亚型、治疗及结局无差异。
  • 该研究为回顾性二次分析,氯胺酮组样本量小(谵妄组54例),置信区间宽,不能据此确立因果关系或改变常规用药。

适用人群与场景

  • 荷兰单中心36张床混合内科-外科ICU,2016年7月至2020年2月连续收治的成人患者。
  • 排除:择期手术后入ICU者、预期生存<48小时者、入ICU时已存在谵妄者、氯胺酮使用前已发生谵妄者。

诊断标准与关键阈值

  • 由受训ICU护士对非昏迷患者(RASS -4/-5)每8小时用CAM-ICU评估。
  • 谵妄日定义为≥1次CAM-ICU阳性 and/or 使用计划性抗精神病药物。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:单中心回顾性队列研究的二次亚组分析;样本量925例成人,单中心。
  • 主要结果:332/925(36%)发生谵妄;谵妄组氯胺酮使用54例(16%),非谵妄组4例(0.7%),p<0.01。
  • 多因素logistic回归:氯胺酮使用aOR 5.60(95%CI 1.09-29.15)、年龄aOR 1.03(95%CI 1.01-1.06)、昏迷aOR 2.10(95%CI 1.15-3.78)、阿片类aOR 171.17(95%CI 66.45-553.68)、苯二氮䓬类aOR 34.07(95%CI 8.12-235.34)均与谵妄独立相关。
  • 氯胺酮与非氯胺酮谵妄组在谵妄持续时间、运动亚型、谵妄治疗及结局方面无差异。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究的二次亚组分析(非RCT),原文未给出证据等级或推荐强度。
  • 局限:单中心、回顾性设计、氯胺酮暴露组样本量小(谵妄组仅54例)、置信区间宽(氯胺酮aOR 95%CI 1.09-29.15),作者明确结论为「可能增加」并呼吁前瞻性研究验证。

对床旁实践的改变

  • 该研究提示氯胺酮镇痛镇静可能与ICU谵妄风险升高相关,在已有谵妄高危因素(高龄、昏迷、使用阿片类或苯二氮䓬类)的患者中处方氯胺酮时应权衡谵妄风险。
  • 研究为回顾性关联分析,置信区间宽且不能排除混杂,不足以据此停用或避免氯胺酮镇痛镇静,也不改变现有谵妄预防流程。
  • 若患者已使用氯胺酮并发生谵妄,原文显示其谵妄特征、治疗及结局与非氯胺酮谵妄无差异,可按常规谵妄管理处理。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: Ketamine is increasingly being used for analgosedation, but its effect on delirium remains unclear. We compared delirium risk variables and ketamine analgosedation use between adults who developed incident delirium and those who did not, evaluated whether ketamine analgosedation increases delirium risk, and compared ICU delirium characteristics, treatments, and outcomes between ketamine and nonketamine patients with delirium.

DESIGN: Secondary, subgroup analysis of a cohort study.

SETTING: Single, 36-bed mixed medical-surgical ICU in the Netherlands from July 2016 to February 2020.

PATIENTS: Consecutive adults were included. Patients admitted after elective surgery, not expected to survive greater than or equal to 48 hours, admitted with delirium, or where delirium occurred prior to ketamine use were excluded.

MEASUREMENTS AND MAIN RESULTS: Trained ICU nurses evaluated patients without coma (Richmond Agitation Sedation Scale. -4/-5) every 8 hours with the Confusion Assessment Method ICU; a delirium day was defined by greater than or equal to1 + Confusion Assessment Method ICU and/or scheduled antipsychotic use. Among 11 variables compared between the delirium and nondelirium groups (Baseline: age, Charlson Comorbidity score, cognitive impairment, admission type, and Acute Physiology and Chronic Health Evaluation-IV score, daily ICU [until delirium occurrence or discharge]: Sequential Organ Failure Assessment score, coma, benzodiazepine, opioid, and ketamine use) and total ICU days, 7 (age, Charlson score, Sequential Organ Failure Assessment score, coma, benzodiazepine, opioid, and ketamine use) were significantly different and were entered, along with delirium occurrence, in a logistic regression model. A total of 332 of 925 of patients (36%) developed delirium. Ketamine use was greater in patients with delirium (54 [16%] vs 4 [0.7%]; p < 0.01). Ketamine use (adjusted odds ratio, 5.60; 95% CI, 1.09-29.15), age (adjusted odds ratio, 1.03; 95% CI, 1.01-1.06), coma (adjusted odds ratio, 2.10; 95% CI, 1.15-3.78), opioid use (adjusted odds ratio, 171.17; 95% CI, 66.45-553.68), and benzodiazepine use (adjusted odds ratio, 34.07; 95% CI, 8.12-235.34) were each independently and significantly associated with increased delirium. Delirium duration, motoric subtype, delirium treatments, and outcomes were not different between the ketamine and nonketamine groups.

CONCLUSIONS: Ketamine analgosedation may contribute to increased ICU delirium. The characteristics of ketamine and nonketamine delirium are similar. Further prospective research is required to evaluate the magnitude of risk for delirium with ketamine use.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Wu TT, Ko S, Kooken R, et al. Exploring Ketamine Analgosedation Use and Its Effect on Incident Delirium in Critically Ill Adults. Crit Care Explor. 2021. PMID: 34604786. doi:10.1097/CCE.0000000000000544

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。